Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. boosted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 144.6% during the third quarter, Holdings Channel reports. The firm owned 34,974 shares of the biopharmaceutical company’s stock after buying an additional 20,676 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Intra-Cellular Therapies were worth $2,559,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Oak Ridge Investments LLC purchased a new stake in shares of Intra-Cellular Therapies in the 2nd quarter worth about $811,000. SG Americas Securities LLC lifted its holdings in shares of Intra-Cellular Therapies by 962.7% in the second quarter. SG Americas Securities LLC now owns 48,778 shares of the biopharmaceutical company’s stock valued at $3,341,000 after purchasing an additional 44,188 shares in the last quarter. Clearbridge Investments LLC grew its position in shares of Intra-Cellular Therapies by 12.3% in the first quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company’s stock valued at $120,723,000 after purchasing an additional 191,416 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Intra-Cellular Therapies during the 1st quarter worth approximately $18,379,000. Finally, Russell Investments Group Ltd. raised its position in shares of Intra-Cellular Therapies by 232.0% during the 1st quarter. Russell Investments Group Ltd. now owns 50,845 shares of the biopharmaceutical company’s stock worth $3,519,000 after purchasing an additional 35,528 shares during the last quarter. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on ITCI. The Goldman Sachs Group lowered their target price on Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Morgan Stanley lifted their price objective on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. UBS Group reduced their target price on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. JPMorgan Chase & Co. raised their price target on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research note on Monday. Finally, Piper Sandler raised shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $68.00 to $92.00 in a research note on Friday, September 6th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $97.23.

Insider Buying and Selling

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 34,396 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $77,962,764.36. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Intra-Cellular Therapies news, CEO Sharon Mates sold 34,396 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $77,962,764.36. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mark Neumann sold 18,714 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the sale, the executive vice president now owns 29,700 shares of the company’s stock, valued at approximately $2,229,876. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 175,316 shares of company stock valued at $13,037,345. 2.60% of the stock is currently owned by corporate insiders.

Intra-Cellular Therapies Stock Down 0.4 %

Shares of NASDAQ ITCI opened at $86.17 on Tuesday. The stock has a market capitalization of $9.14 billion, a PE ratio of -99.04 and a beta of 0.97. The firm has a fifty day moving average of $75.41 and a 200-day moving average of $73.31. Intra-Cellular Therapies, Inc. has a 52-week low of $52.88 and a 52-week high of $88.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The firm had revenue of $175.40 million for the quarter, compared to analyst estimates of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business’s revenue was up 39.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.25) earnings per share. Equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.63 EPS for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.